- Patent Title: Anti-PD1 antibodies and their use as therapeutics and diagnostics
-
Application No.: US15802093Application Date: 2017-11-02
-
Publication No.: US09988450B2Publication Date: 2018-06-05
- Inventor: Kang Li , Tong Zhang , Jing Song , Lanlan Xu , Qi Liu , Hao Peng
- Applicant: BeiGene, Ltd.
- Applicant Address: CH Zurich
- Assignee: BEIGENE SWITZERLAND GMBH
- Current Assignee: BEIGENE SWITZERLAND GMBH
- Current Assignee Address: CH Zurich
- Agency: Cooley LLP
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61K39/00
Abstract:
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Public/Granted literature
- US20180111995A1 ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS Public/Granted day:2018-04-26
Information query
